Christopher Davis

Company: Apertura Gene Therapy

Job title: Manager, Scientific Research

Seminars:

Reprogramming AAV Capsids to Target Human Receptors for Enhanced CNS Delivery 12:00 pm

Optimizing for translation in the clinic should start with capsids interacting with human receptors Regulatory guidance in gene therapy and direct FDA feedback across multiple programs outlines preclinical path for human-specific capsid and use of humanized animal models Surrogate mouse BBB-crossing capsids can be used in efficacy studies in parallel with distribution studies enabling dose…Read more

day: Conference Day One